Abstract | BACKGROUND: METHODS: Eighteen non-diabetic renal transplant recipients evaluated at our unit for more than 1 year after transplantation (13-155 months) were enrolled. Losartan was administered for a period of 14. 2+/-6.86 (6-28) months at a dose of 25-100 mg/day depending on the antihypertensive response obtained. RESULTS:
Losartan satisfactorily lowered systemic blood pressure. Overall graft function remained stable and a significant reduction in proteinuria was observed throughout the period on Losartan (1.0+/-0.87 vs 0.4+/-0.83 g/l, P=0. 003). No serious side-effects were reported except for a significant reduction in the mean haemoglobin concentration (from 13.5+/-1.74 g/dl to 12.2+/-2.19 g/dl; P=0.001). CONCLUSIONS: A satisfactory antihypertensive effect was observed with long-term therapy with Losartan. A significant reduction in proteinuria without adversely affecting graft function was the main beneficial effect observed. Losartan was generally well tolerated and a decrease in haemoglobin was the major side-effect.
|
Authors | J Calviño, X M Lens, R Romero, D Sánchez-Guisande |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 15
Issue 1
Pg. 82-6
(Jan 2000)
ISSN: 0931-0509 [Print] England |
PMID | 10607772
(Publication Type: Journal Article)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
- Hemoglobins
- Receptor, Angiotensin, Type 1
- Receptor, Angiotensin, Type 2
- Losartan
|
Topics |
- Adult
- Aged
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Blood Pressure
(drug effects)
- Female
- Hemoglobins
(metabolism)
- Humans
- Hypertension
(drug therapy, etiology, physiopathology)
- Kidney Transplantation
(adverse effects, physiology)
- Losartan
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Proteinuria
(drug therapy)
- Receptor, Angiotensin, Type 1
- Receptor, Angiotensin, Type 2
|